Improving the Standard of Care for Solid Tumor Cancer Treatment
The current standard of care for most solid tumor cancers involves the use of fractionated doses of radiation combined with chemotherapeutics, often termed "chemoradiotherapy." This can be a highly toxic treatment regimen that results in adverse side effects. Radiation can damage surrounding normal tissues and chemotherapeutics often create dose-limiting toxicities that can halt their use, resulting in suboptimal treatment and costly additional care. While marginal improvements have been made with current chemoradiation treatments, survival rates and side effects that greatly compromise quality of life have not improved to any significant degree.
BIO 300 represents a new class of drug in cancer treatments. Its ability to sensitize tumor cells to radiation-induced killing, while at the same time protect normal tissues from the side effects of radiation is unprecedented.
It is estimated that there were 1,658,370 new cases of cancer In the United States in 2015. The prevalence of radiotherapy is estimated to be between 29%-66% for all cancer patients. This suggests 483,000 to 1.1 million patients with newly diagnosed cancers in 2015 will receive radiation therapy. In addition, the demand for radiation therapy during the initial treatment course is expected to increase by 22% from 2010-2020 as a result of an aging population.
Cancers most commonly treated with radiation are breast, prostate, lung, head and neck, and colorectal.